MaxCyte Inc. (MXCT)

Name: MaxCyte Inc. (MXCT) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: MaxCyte Inc. (MXCT)

Stock Card

$1.22

$-0.06 (-4.69%)

As on 28-Aug-2026 16:01EDT

Market cap

$126 Mln

Revenue (TTM)

$31 Mln

P/E Ratio

P/B Ratio

0.8

Div. Yield

0 %

MaxCyte (MXCT) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.21 High: 1.30

52 Week Range

Low: 0.64 High: 1.87

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.2 %
ROCE

-- %
Industry P/E

44.46
EV/EBITDA

-11.1
Debt to Equity

0
Book Value

$1.5
EPS

$-0.3
Face value

--
Shares outstanding

103,206,206

10 Years Aggregate

CFO

$-89.34 Mln

EBITDA

$-124.44 Mln

Net Profit

$-129.46 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
MaxCyte (MXCT)	-21.3	19.6	13.0	-12.9	-30.7	-40.1	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
MaxCyte (MXCT)	-62.7	-11.4	-13.9	-46.4
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
MaxCyte (MXCT)	1.2	125.9	31.1	-35.6	-86.2	-21.6	--	0.8
10X Genomics Inc (TXG)	61.5	8,018.1	616.9	-75.1	1.7	-9.3	--	10.2
Avantor (AVTR)	14.6	9,638.1	6,561.1	-578.0	-4.5	-10.3	--	1.7
Bio-Rad Laboratories	365.1	9,761.6	2,589.3	222.4	-6.0	3	44.5	1.3
Bruker (BRKR)	57.1	8,696.7	3,499.6	-71.2	0.5	-3.2	--	3.8
Glaukos Corp (GKOS)	179.9	10,905.5	612.8	-188.1	-30.6	-28.1	--	16.4
Lantheus Holdings (LNTH)	100.8	6,577.5	1,556.3	275.3	24.6	22.9	24.1	5.0
Merit Medical Systems (MMSI)	90.5	5,403.2	1,579.2	145.6	14.3	8.9	37.2	3.2
Penumbra (PEN)	321.7	12,752.7	1,504.9	160.6	13.6	10.9	79.4	8.4
Repligen (RGEN)	176.3	9,947.9	785.1	41.5	9.9	2	251.8	4.9

Shareholding Pattern

View Details

About MaxCyte (MXCT)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale... transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. Read more

President, CEO, Secretary & Director

Mr. Maher Masoud
President, CEO, Secretary & Director

Mr. Maher Masoud
Headquarters

Rockville, MD
Website

https://www.maxcyte.com

FAQs for MaxCyte (MXCT)

What is the current share price of MaxCyte Inc (MXCT) Today?

The share price of MaxCyte Inc (MXCT) is $1.22 (NASDAQ) as of 28-Aug-2026 16:01 EDT. MaxCyte Inc (MXCT) has given a return of -30.66% in the last 3 years.

What is the current PB & PE ratio of MaxCyte Inc (MXCT)?

Since, TTM earnings of MaxCyte Inc (MXCT) is negative, P/E ratio is not available.
The P/B ratio of MaxCyte Inc (MXCT) is 0.83 times as on 28-Aug-2026, a 78 discount to its peers’ median range of 3.79 times.

PE & PB ratio at the end of financial year.